The “Streinth” laboratory aims at developing a dynamic translational research on cancers through an interactive group of scientists and clinicians affiliated to INSERM, Paul Strauss Cancer Center, and Strasbourg University Hospitals. Our goal is to propose innovative and more efficient treatments by deciphering the causes behind the variability in therapeutic responses. Our strategy is to characterize the impact of chemo/chemo-radiation therapies on the interactions between the cancer cells and their specific metabolic and cellular microenvironment with the objective of discovering key effectors that might represent prognostic markers and/or drugable targets. More precisely, we are focusing on the contribution of epigenetic processes in the interplay between metabolic stress response pathways activated by the microenvironment and gene regulations driven by the complex family of the p53 tumor suppressor gene (p53, p63, p73). We are mostly focusing on cancers of the aero-digestive system (i.e. gastric, oesophagus, colon, head & neck, lung) as well as healthy tissues affected by the therapies (muscle, nervous system).
To address these questions, we propose a translational research that includes fundamental molecular studies extending them into the pathophysiological context using animal models (i.e. transgenics gastric cancer mouse model) and clinical investigations (i.e. biobanks for gastric and head/neck cancers). Our results are also the bases for the development of innovative mono or combined therapies targeting the cellular metabolism, which already led to several patents. We believe that our projects will uncover innovative tolls for treatment decision making and therapeutic protocols that will be translated from bench to bed in the frame of clinical trials. The rapid transfer of our findings will be facilitated in the future by the proximity of the “Regional Cancer Institute”.